HBSP (USA)
-
Hitachi Rail Limited (B)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721365-EStrategyDescribes the strategy and organisation changes made by British executive, Alistair Domer, after he is made head of Hitachi Rail's global business. The company acquires an Italian company, continues to win contracts in the UK, but struggles to bring its gStarting at €5.74
-
Takeda Pharmaceutical Company Limited (B)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721374-EStrategyThis case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challengeStarting at €5.74
-
Choosing the Right Esports Business Model
Collis, David J.; MacKay, Alexander J.Case HBS-719459-EStrategyTwo esports entrepreneurs must choose on which business model to focus their time and money. After successfully launching an online esports coaching platform, a number of new opportunities emerge in the rapidly growing esports space which now has close to 1 billion gamers and an online audience that is greater than the Superbowl. Should they focus on a B2C business, a B2B business? Develop an analytics capability to support "sabremetrics" for esp...Starting at €8.20
-
Hitachi Rail Limited (A)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721364-EStrategyHitachi must decide whether to make a British executive, who has successfully built its European rail business from scratch, head of its global rail division even though the bulk of revenues for the unit still come from Japan. The case describes, the histStarting at €8.20
-
Takeda Pharmaceutical Company Limited (A)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721373-EStrategyThis case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition woStarting at €8.20